Document Detail

Differentiation of low molecular weight heparins in acute coronary syndromes: an interventionalist's perspective.
MedLine Citation:
PMID:  10549727     Owner:  NLM     Status:  MEDLINE    
The more predictable and sustained anticoagulant effects of low molecular weight heparins (LMWHs) compared with unfractionated heparin (UFH) has led to increasing interest in their potential use in association with interventional cardiac procedures. Available data demonstrate that dalteparin, nadroparin, reviparin and enoxaparin can be safely used during percutaneous transluminal coronary angioplasty. As yet there is, however, no evidence of a reduction in restenosis. Preliminary evidence indicates that a novel antithrombotic combination of ticlodipine and enoxaparin in association with coronary stenting may reduce the frequency of acute events compared with conventional antithrombotic therapy, although it remains unclear as to whether ticlopidine alone is equally effective. Enoxaparin also reduces the frequency of ischemic events following thrombolytic therapy for acute myocardial infarction, and is the only LMWH to have been shown to reduce the frequency of revascularization procedures in patients with acute coronary syndromes. Some evidence suggests that, in patients with acute coronary syndromes, plaque passivation may be adequately managed using long-term LMWH therapy, rather than immediate intervention, given the potential increase in thromboembolic burden by the interventional procedure. On the basis of available evidence, peri-interventional use of LMWH is broadly feasible. Given the United States Food and Drug Administration's position that LMWHs are distinct noninterchangeable drugs, further trials are needed to establish acceptable protocols and the LMWH of choice. Until that time, interventional cardiologists can rely on available clinical data to choose a LMWH that will simplify patient management and improve patient outcome.
D Gulba
Related Documents :
9784797 - Antiplatelet therapy in coronary artery disease: review and update of efficacy studies.
18440347 - High-dose atorvastatin does not negatively influence clinical outcomes among clopidogre...
15078587 - Should people on aspirin avoid ibuprofen? a review of the literature.
9822087 - Reduction in complications of angioplasty with abciximab occurs largely independently o...
10994937 - Coronary angioplasty in patients with unstable angina: clinical, electrocardiographic a...
24590407 - Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke a...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Seminars in thrombosis and hemostasis     Volume:  25 Suppl 3     ISSN:  0094-6176     ISO Abbreviation:  Semin. Thromb. Hemost.     Publication Date:  1999  
Date Detail:
Created Date:  1999-12-08     Completed Date:  1999-12-08     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0431155     Medline TA:  Semin Thromb Hemost     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  123-7     Citation Subset:  IM    
Charité, Humboldt University at Berlin, Franz-Volhard Clinic, Division of Clinical and Molecular Cardiology, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Clinical Trials as Topic
Coronary Disease / drug therapy*
Heparin, Low-Molecular-Weight / therapeutic use*
Myocardial Revascularization
Reg. No./Substance:
0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction.
Next Document:  Optimizing anticoagulant therapy in the management of pulmonary embolism.